The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: transforming growth factor alpha expression as a marker for the stage of progression
- PMID: 7600545
- DOI: 10.1016/0304-3835(95)03789-Y
The quantitation of altered hepatic foci during multistage hepatocarcinogenesis in the rat: transforming growth factor alpha expression as a marker for the stage of progression
Abstract
The experimental three-stage hepatocarcinogenesis protocol of initiation, promotion, and progression, coupled with the analytical technique of stereology, permits quantitative analysis of the carcinogenic process, including the derivation of biologically based risk assessment models. The aberrant expression of the placental isozyme of glutathione S-transferase (PGST) is an efficient marker for initiated, preneoplastic, and neoplastic hepatocytes. Putatively initiated cells and their clonal progeny can be identified, enumerated, and their growth characteristics determined on the basis of their aberrant expression of this protein. A lack of suitable markers has made the identification and quantitation of hepatocytes in the early stage of progression more difficult. One characteristic of cells in the stage of progression is the evolution of relatively autonomous growth. The alteration of growth factor signalling pathways may provide one mechanism for this observation. The expression of transforming growth factor alpha (TGF alpha) is seen in many malignancies. The initiation-promotion-progression protocol has been used to induce progression in the rat liver. The focal expression of TGF alpha was found to correlate with areas of progression in rats subjected to this protocol. The ability to identify and quantitate cells in the stage of progression should facilitate application of the Moolgavkar-Venzon-Knudson model for assessing human risk from carcinogens active at each of these three stages. Validation of this model will require determination of the number and growth characteristics of hepatocytes in the stage of progression.
Similar articles
-
Transforming growth factor-alpha in carcinogen-induced F344 rat hepatic foci.Toxicol Appl Pharmacol. 1996 Sep;140(1):131-45. doi: 10.1006/taap.1996.0206. Toxicol Appl Pharmacol. 1996. PMID: 8806879
-
Comparison of experimental and theoretical parameters of the Moolgavkar-Venzon-Knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis.Toxicology. 1995 Sep 1;102(1-2):161-75. doi: 10.1016/0300-483x(95)03045-h. Toxicology. 1995. PMID: 7482551 Review.
-
Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat.Cancer Res. 1996 Jul 1;56(13):2985-91. Cancer Res. 1996. PMID: 8674052
-
Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.Am J Pathol. 1996 Aug;149(2):407-28. Am J Pathol. 1996. PMID: 8701981 Free PMC article.
-
Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis.Prog Clin Biol Res. 1994;387:113-38. Prog Clin Biol Res. 1994. PMID: 7972243 Review.
Cited by
-
Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats.Am J Pathol. 1997 Mar;150(3):1071-87. Am J Pathol. 1997. PMID: 9060843 Free PMC article.
-
Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile.Sci Rep. 2017 Mar 6;7:43745. doi: 10.1038/srep43745. Sci Rep. 2017. PMID: 28262799 Free PMC article.
-
Stage-specific gene expression during hepatocarcinogenesis in the rat.J Cancer Res Clin Oncol. 1996;122(5):257-65. doi: 10.1007/BF01261401. J Cancer Res Clin Oncol. 1996. PMID: 8609148 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical